Check-Cap (STU:7CC) Tariff Resilience Score: 0/10 (As of Jul. 10, 2026)


STU:7CC Check-Cap Ltd STU:7CC
30 GF Score
Price €1.03
! 2 Warning Signs
View Full Analysis

What is Check-Cap Tariff Resilience Score?

Check-Cap has the Tariff Resilience Score of 0, which implies that the company might have .

Check-Cap has Check-Cap Ltd, a medical device company, has limited exposure to tariffs due to its niche market and potential for tariff exemptions on medical products. Its global supply chain could pose some risk, but overall impact is moderate.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Check-Cap might have .

Check-Cap  (STU:7CC) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Check-Cap Tariff Resilience Score Related Terms

STU:7CC
30GF Score
Check-Cap Ltd STU:7CC
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Check-Cap Business Description

Other Exchanges MBAI:USA
Address 29 Abba Hushi Avenue, P.O. Box 1271, Mount Carmel, Isfiya, ISR, 3009000
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but plans to market products in the United States, Europe, Israel and Japan.
30GF Score

Get the complete analysis for STU:7CC

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.03
Price